TScan Therapeutics Inc (TCRX)
8.99
+0.09
(+1.01%)
USD |
NASDAQ |
May 17, 16:00
8.99
0.00 (0.00%)
Pre-Market: 20:00
TScan Therapeutics Total Liabilities (Quarterly): 117.86M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 117.86M |
| December 31, 2023 | 121.28M |
| September 30, 2023 | 122.42M |
| June 30, 2023 | 126.32M |
| March 31, 2023 | 95.56M |
| December 31, 2022 | 99.66M |
| September 30, 2022 | 48.80M |
| Date | Value |
|---|---|
| June 30, 2022 | 20.76M |
| March 31, 2022 | 22.51M |
| December 31, 2021 | 27.33M |
| September 30, 2021 | 30.82M |
| June 30, 2021 | 190.04M |
| March 31, 2021 | 190.86M |
| December 31, 2020 | 92.20M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
20.76M
Minimum
Jun 2022
190.86M
Maximum
Mar 2021
93.31M
Average
97.61M
Median
Total Liabilities (Quarterly) Benchmarks
| AnaptysBio Inc | 358.06M |
| CEL-SCI Corp | 15.74M |
| AIM ImmunoTech Inc | 9.147M |
| IGC Pharma Inc | 2.206M |
| NovaBay Pharmaceuticals Inc | 5.197M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 240.83M |
| Shareholders Equity (Quarterly) | 122.97M |
| Debt to Equity Ratio | 0.246 |
| Current Ratio | 5.233 |
| Net Debt Paydown Yield | -0.05% |